Here, we characterize BTBD1 (9) expression in CRC, assess its associations with clinicopathological features and prognosis, and use multi-omics analyses to explore its functional roles in tumor progression and immune infiltration-with the goal of evaluating BTBD19 as a potential CRC biomarker. Here, BTBD19 is linked to neoplasm.